摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-肼基-N-甲基苯甲烷磺酰胺盐酸盐 | 88933-16-8

中文名称
4-肼基-N-甲基苯甲烷磺酰胺盐酸盐
中文别名
4-苯肼-N-甲基甲烷磺酰胺;4-苯肼-N-甲基甲烷磺酰胺盐酸盐;4-肼基-N-甲基苯甲烷磺酰胺;N-甲基-4-肼基苯甲磺酰胺
英文名称
4-hydrazino-N-methylbenzenemethanesulfonamide hydrochloride
英文别名
4-Hydrazino-N-methylbenzenemethanesulphonamide hydrochloride;C-(4-hydrazino-phenyl)-n-methyl-methanesulfonamide hydrochloride;4-(N-(methyl)aminosulphonylmethyl)-phenylhydrazine hydrochloride;1-(4-Hydrazinylphenyl)-N-methylmethanesulfonamide hydrochloride;1-(4-hydrazinylphenyl)-N-methylmethanesulfonamide;hydrochloride
4-肼基-N-甲基苯甲烷磺酰胺盐酸盐化学式
CAS
88933-16-8
化学式
C8H13N3O2S*ClH
mdl
——
分子量
251.737
InChiKey
WZZPGBAXFSIKJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    170-173°C
  • 溶解度:
    DMSO(轻微)、甲醇(轻微、加热、超声处理)、水(轻微)

计算性质

  • 辛醇/水分配系数(LogP):
    0.44
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    92.6
  • 氢给体数:
    4
  • 氢受体数:
    5

安全信息

  • 危险品标志:
    Xi
  • RTECS号:
    DI4357500
  • 安全说明:
    S26,S36/37/39
  • 危险类别码:
    R20/21/22
  • 包装等级:
    III
  • 危险品运输编号:
    3276
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    | 冰箱 |

SDS

SDS:b2df5cb5ab5a4563025d002c5e64f2f3
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] Pyrazolopyrrolidine compounds<br/>[FR] COMPOSÉS PYRAZOLOPYRROLIDINE
    申请人:NOVARTIS AG
    公开号:WO2013080141A1
    公开(公告)日:2013-06-06
    The invention relates to compounds of formula (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
    该发明涉及公式(I)所述的化合物,包括这些化合物的药物制剂,以及这些化合物在治疗由MDM2和/或MDM4活性介导的疾病或疾病中的用途和使用方法,以及包含这些化合物的组合物。
  • Indole derivative
    申请人:Glaxo Group Limited
    公开号:US05037845A1
    公开(公告)日:1991-08-06
    A compound of formula (I) ##STR1## and its physiologically acceptable salts and solvates are described as useful in treating and/or preventing pain resulting from dilatation of the cranial vasculature in particular migraine. The compound (I) may be prepared, for example, by cyclizing a compound of formula (II) ##STR2##
    描述了一种化合物,其化学式为(I)##STR1##及其生理上可接受的盐和溶剂,用于治疗和/或预防由颅内血管扩张引起的疼痛,特别是偏头痛。该化合物(I)可以通过环化化合物的方法制备,例如,通过环化化合物的方法制备化合物的方法(II)##STR2##
  • Indolyl compounds and their use in treatment of cephalic pain
    申请人:Glaxo Group Limited
    公开号:US05475020A1
    公开(公告)日:1995-12-12
    The invention relates to indoles of general formula (I) ##STR1## wherein R.sub.0 represents a hydrogen atom or a C.sub.1-3 alkyl group; R.sub.1 represents a group R.sub.4 CONH--, R.sub.4 R.sub.5 NSO.sub.2 --, R.sub.4 SO.sub.2 NH-- or R.sub.4 R.sub.5 NCO-- (where R.sub.4 is a hydrogen atom or a C.sub.1-6 alkyl group, provided that R.sub.4 does not represent a hydrogen atom when R.sub.1 represents R.sub.4 SO.sub.2 NH--, and R.sub.5 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, phenyl or phen(C.sub.1-3)alkyl group in which the phenyl ring is optionally substituted by a halogen atom or a C.sub.1-4 alkoxy, hydroxy or C.sub.1-3 alkyl group); R.sub.2 is a hydrogen atom, a C.sub.1-3 alkyl, a C.sub.3-6 alkenyl, a phenyl or a phen(C.sub.1-3)alkyl group; R.sub.3 is a hydrogen atom, a C.sub.1-3 alkyl group or a group --CO.sub.2 R.sub.6, --COR.sub.6, --COCO.sub.2 R.sub.6 or --CONHR.sub. 6 where R.sub.6 is a hydrogen atom or a C.sub.1-4 alkyl, a C.sub.3-7 cycloalkyl, a C.sub.3-6 alkenyl, an aryl or an ar(C.sub.1-4)alkyl group in which the aryl group may be unsubstituted or substituted by a halogen atom or a C.sub.1-4 alkoxy, C.sub.1-4 alkyl or hydroxy group, provided that when R.sub.3 is --CO.sub.2 R.sub.6, R.sub.6 is other than hydrogen; n is zero or an integer from 1 to 5; and pharmaceutically acceptable salts thereof.
    该发明涉及通式(I)的吲哚化合物 其中R0代表氢原子或C1-3烷基基团;R1代表基团R4CONH-、R4R5NSO2-、R4SO2NH-或R4R5NCO-(其中R4为氢原子或C1-6烷基基团,但当R1代表R4SO2NH-时,R4不代表氢原子,而R5为氢原子或C1-6烷基、C3-7环烷基、苯基或苄基,其中苯环可以选择性地被卤原子或C1-4烷氧基、羟基或C1-3烷基基团取代);R2为氢原子、C1-3烷基、C3-6烯基、苯基或苄基;R3为氢原子、C1-3烷基或基团--CO2R6、--COR6、--COCO2R6或--CONHR6,其中R6为氢原子或C1-4烷基、C3-7环烷基、C3-6烯基、芳基或芳基(C1-4)烷基基团,其中芳基基团可以是未取代或被卤原子或C1-4烷氧基、C1-4烷基或羟基基团取代,但当R3为--CO2R6时,R6不是氢原子;n为零或1到5之间的整数;及其药学上可接受的盐。
  • Heterocyclic compounds
    申请人:Glaxo Group Limited
    公开号:US04816470A1
    公开(公告)日:1989-03-28
    Indole derivatives of the general formula (I) are disclosed: ##STR1## where R.sub.1 is H or an alkyl or alkenyl group, R.sub.2 is H, or an alkyl, alkenyl, aryl, aralkyl or cycloalkyl group; R.sub.3 is H or an alkyl group; R.sub.4 and R.sub.5 are independently H or an alkyl or propenyl group or together form an aralkylidene group; and Alk is an optionally substituted alkylene chain; and their physiologically acceptable salts and solutes. These compounds are potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner. Various methods for the production of the compounds are disclosed including a Fischer-indole cyclization process.
    通式(I)的吲哚衍生物已被披露:其中R.sub.1是H或烷基或烯基基团,R.sub.2是H,或烷基、烯基、芳基、芳基烷基或环烷基基团;R.sub.3是H或烷基基团;R.sub.4和R.sub.5独立地是H或烷基或丙烯基团,或者一起形成芳基烷基亚甲基团;Alk是一个可选择取代的烷基链;以及它们的生理上可接受的盐和溶质。这些化合物可能对偏头痛的治疗有用,并可按照常规方式制备为药物组合物。披露了用于生产这些化合物的各种方法,包括一种Fischer-吲哚环化过程。
  • A General Synthesis of Substituted Indoles from Cyclic Enol Ethers and Enol Lactones
    作者:Kevin R. Campos、Jacqueline C. S. Woo、Sandra Lee、Richard D. Tillyer
    DOI:10.1021/ol036113f
    日期:2004.1.1
    [reaction: see text] X = CH2, C[double bond]O, R2 = H, alkyl. A general method was developed for the one-pot synthesis of highly functionalized indoles from simple, commercially available aryl hydrazines and cyclic enol ethers. Enol lactones were also used as substrates, affording substituted indole acetic acid or indole propionic acid derivatives. This procedure affords 2,3-disubstituted indoles as
    [反应:见正文] X = CH 2,C [双键] O,R 2 = H,烷基。已开发了一种通用方法,用于从简单的市售芳基肼和环状烯醇醚一锅合成高官能化的吲哚。烯醇内酯也用作底物,提供取代的吲哚乙酸或吲哚丙酸衍生物。该方法由适当取代的烯醇醚或烯醇内酯得到2,3-二取代的吲哚,作为单一的区域异构体。该方法在抗偏头痛药物舒马曲坦和消炎药消炎痛的有效合成中得到了强调。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐